Business Wire

Ares Management Launches First ELTIF to Expand Access to European Direct Lending Strategy

19.6.2025 13:00:00 EEST | Business Wire | Press release

Share

Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today the launch of its first European Long-Term Investment Fund (“ELTIF”) vehicle, the Ares European Strategic Income ELTIF Fund (“AESIF ELTIF”), a semi-liquid perpetual direct lending fund that will provide individual investors in the European Economic Area with expanded access to Ares’ leading European Direct Lending strategy.

AESIF ELTIF is the latest offering through the wealth channel and its first under the updated ELTIF regime. Designed to deliver a diversified portfolio largely comprising directly originated, senior secured floating rate loans to businesses in Western Europe, AESIF ELTIF seeks to provide a durable income solution with downside protection and yield stability. AESIF ELTIF is intended to widen individual investor participation in Ares’ European Direct Lending strategy through lower investment minimums relative to traditional alternative investment products.

Ares launched its European Direct Lending strategy in 2007, gaining a first mover advantage, and has established itself as a market leader. The strategy comprises approximately 95 investment professionals operating across seven offices in Europe and managed over $77 billion in assets, as of March 31, 2025. Since its inception, the European Direct Lending business has completed over 390 investments totaling more than €73 billion.

“Ares strongly believes in our ability to provide individual investors with attractive investment solutions as they seek to diversify their portfolios in response to volatility and uncertainty in the public markets,” said Andrea Fernandez, Head of Product Management and Investor Relations for European Credit, and Daniel Sinclair, Partner in European Direct Lending. “As part of this commitment, AESIF ELTIF enables us to offer qualifying individuals the same high-quality, localized origination and strong portfolio management capabilities we offer our institutional investors.”

“We are pleased to further expand access to our leading European direct lending capabilities for individual investors in Europe, underscoring the strong demand for income-producing asset classes such as private credit,” said Mark Serocold, Partner and EMEA Head of Wealth Management Solutions. “The updated ELTIF regime is aligned to our mission of democratizing private markets investments, and we believe we will continue seeing a shift in allocations to the private markets as a wider pool of qualifying individual investors become eligible to participate.”

Since the launch of the wealth channel in 2021, Ares has remained focused on scaling its wealth platform to deliver private markets access and education to financial advisors and their clients. With a growing team of approximately 150 professionals located in offices throughout the U.S., Europe and Asia, Ares’ wealth channel represents one of the most resourced wealth distribution and client service platforms in the alternatives industry today.

About Ares Management Corporation

Ares Management Corporation (NYSE: ARES) is a leading global alternative investment manager offering clients complementary primary and secondary investment solutions across the credit, real estate, private equity and infrastructure asset classes. We seek to provide flexible capital to support businesses and create value for our stakeholders and within our communities. By collaborating across our investment groups, we aim to generate consistent and attractive investment returns throughout market cycles. As of March 31, 2025, Ares Management Corporation's global platform had approximately $546 billion of assets under management, with operations across North America, South America, Europe, Asia Pacific and the Middle East. For more information, please visit www.aresmgmt.com.

Disclaimers

Interests in AESIF ELTIF have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “Securities Act”), or the applicable securities laws of any United States state or any non-United States jurisdiction. The interest in AESIF ELTIF may not be offered, sold or delivered directly or indirectly in the United States or to or for the account or benefit of any “U.S. Person” except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and any applicable state laws. As such, any “U.S. Person” may not receive and should not act or rely on this Press Release or any other materials related to AESIF ELTIF.

The information contained in this Press Release is being made available solely for information purposes. Any potential investors are urged to carefully read the applicable Prospectus and other materials in their entirety before making an investment decision. Any potential investors should conduct their own investigations and analysis of Ares, AESIF ELTIF and the information set forth in the applicable Prospectus and other materials. Nothing in this Press Release or the other applicable materials should be construed as a recommendation to invest in any securities or as legal, accounting or tax advice. Before making any decision to invest in AESIF ELTIF, potential investors should carefully review information relating to Ares and AESIF ELTIF and consult with their own legal, accounting, tax and other advisors when considering the merits of any investment. There can be no assurance that AESIF ELTIF will meet its investment objectives or otherwise be able to successfully carry out its investment program. There can be no assurance that an investor will receive a return on its capital, and therefore, an investor should only invest in AESIF if such investor is able to withstand a total loss of its investment.

All data as of March 31, 2025. Diversification does not assure profit or protect against market loss. References to downside protection are not guarantees against loss of investment capital or value.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250618926989/en/

Contacts

Investors:
awmseurope@aresmgmt.com

Media:
Giles Bethule, +44 7879615114
media.europe@aresmgmt.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

EADV 2026: Galderma to Unveil New Data Advancing Understanding of Skin Diseases, Skin Longevity, and Real-world Patient Experiences23.9.2026 08:00:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, will present 19 abstracts and deliver a broad scientific education program at the 2026 European Academy of Dermatology and Venereology (EADV) Congress. Through these activities, Galderma will showcase how it continues to advance its pipeline and the science of dermatology, deepening understanding of biological and quality-of-life factors, while driving innovation in targeted treatments, skin longevity and evidence-based care. “At Galderma, we recognize that advancing dermatology means not only addressing the needs of patients living with common chronic skin conditions, such as atopic dermatitis and acne, but also anticipating the trends that will shape the future of skin health. Our presence at EADV demonstrates our unique ability to achieve this, with new data spanning both established areas of unmet need and emerging fields such as skin longevity, helping drive innovation and meaningful outcomes for patients today and i

Oticon Medical Launches SmartCharger for the Ponto 5 Family23.9.2026 08:00:00 EEST | Press release

Oticon Medical today announces the launch of SmartCharger for the Ponto 5 family, introducing its first rechargeable solution for percutaneous sound processors and marking a new step in convenience and portability for bone anchored hearing system users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922863462/en/ Oticon Medical today announces the launch of SmartCharger for the Ponto 5 family, introducing its first rechargeable solution for percutaneous sound processors and marking a new step in convenience and portability for bone anchored hearing system users. Powering the Ponto 5 family The launch of SmartCharger underlines Oticon Medical’s continued commitment to the Ponto family, which includes Ponto 5 SuperPower, the world’s most powerful abutment-level sound processor,1 and Ponto 5 Mini, the world’s smallest percutaneous sound processor.1 By bringing rechargeable convenience to the Ponto sound processors, Oticon Me

Textron Aviation Marks 500th Cessna Citation Latitude Rollout22.9.2026 17:19:00 EEST | Press release

Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, today announced the rollout of the 500th Cessna Citation Latitude business jet from the company’s Wichita, Kansas, manufacturing facility. The production milestone highlights the continued success of the world’s best-selling midsize business jet and recognizes the employees whose craftsmanship and dedication have helped make the Citation Latitude the trusted choice for operators around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922867287/en/ Textron Aviation marks 500th Cessna Citation Latitude rollout. (Photo Credit: Textron Aviation) “The rollout of the 500th Citation Latitude is a testament to the employees who build this aircraft with dedication and pride every day,” said Eric Cardinali, senior vice president, Manufacturing. “Behind every aircraft is a team committed to delivering the quality and craftsmanship our customers expect. This milestone

OCP Announces Date of Second Quarter and First Half 2026 Earnings22.9.2026 17:00:00 EEST | Press release

OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its second quarter and first half 2026 results on Tuesday, September 29, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 10:00 a.m. EDT, 2:00 p.m. Morocco (GMT) and 3:00 p.m. London time (GMT+1). OCP senior management will host a conference call to discuss second quarter and first half 2026 results at 11:00 a.m. EDT, 3:00 p.m. Morocco (GMT) and 4:00 p.m. London time (GMT+1) on Tuesday, September 29, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century

Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 202622.9.2026 16:30:00 EEST | Press release

Takeda(TSE:4502/NYSE:TAK)announced that new data from its oncology pipeline and portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026, in Madrid, Spain. Key data will include a late-breaking abstract on arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343*) and two presentations on TAK-928 (Innovent R&D code: IBI363*). Clinical and real-world analyses of ALUNBRIG® (brigatinib) and FRUZAQLA® (fruquintinib) will also be shared at the congress. “Takeda’s data at ESMO reflect our commitment to delivering rapid progress for patients living with some of the most prevalent and challenging cancers, including advanced gastric cancer and immunotherapy-resistant and previously untreated non-small cell lung cancer,” said Phuong Khanh (P.K.) Morrow, M.D., Head of the Oncology Therapeutic Area Unit at Takeda. “Our mission is to advance new therapeutic approaches for patients who need more options or who remain underserved by cur

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye